Overview

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-01-10
Target enrollment:
Participant gender:
Summary
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants.
Phase:
PHASE2
Details
Lead Sponsor:
Clexio Biosciences Ltd.